BioNTech Investor Presentation Deck
2021: Key Highlights of Progress Towards Vision
8
COMIRNATY -
GLOBAL LEADERSHIP
Five randomized
phase 2 trials
~2.6 bn
doses delivered to
in 2021¹
> 165
Countries &
territories ¹
DROVE ADVANCEMENT IN ONCOLOGY
Four new platforms entered
the clinic (FIH)
EXPANDED GLOBAL ORGANIZATION
3,000+ team members
Increased footprint with new offices in U.S.,
Europe and Asia
>1 bn
to low- and middle-
income countries ¹
Three strategic M&As
to complement existing technologies
STRONG FINANCIAL PERFORMANCE
€19.0 Bn
€39.63
Total 2021 Revenues²
Diluted EPS²
1 As of end 2021; 2 Estimated figures based on preliminary data shared between Pfizer and BioNTech as further described in our Annual Report on Form 20-F for the year ending December 31, 2021; FIH: First in humans
BIONTECHView entire presentation